JURISDICTION SPECIFIC MEDICARE PART B

ELIGARD (leuprolide acetate)

POLICY

L COVERED USES

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

The list of covered ICD-10 codes is prohibitively long to include within this policy. A complete list can be found at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. The FDA-labeled indications are listed below:

Prostate cancer

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available in a legible format with patient identification information (e.g., complete name and dates of service) and signature of physician or non-physician practitioner responsible for and providing care to the member, upon request, for all submissions:

- A. Relevant medical history
- B. Physical examination
- C. Results of pertinent diagnostic tests
- D. Any relevant procedures

III. CRITERIA FOR APPROVAL

Prostate Cancer

Authorization of 12 months may be granted for treatment of advanced prostate cancer when orchiectomy and/or estrogen administration is either not indicated or is unacceptable to the member.

IV. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Eligard 4013-A Med B Jurisdiction H (AR, CO, LA, MS, NM, OK, TX) and L (DC, DE, MD, NJ, PA) P2022.docx © 2022 CVS Caremark. All rights reserved

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s)

4013-A

V. REFERENCES

- 1. Luteinizing Hormone-Releasing Hormone (LHRH) Analogs LCD (L34822) Version R6. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed February 10, 2022.
- 2. Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (A56776) Version R2. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed February 10, 2022.
- 3. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; April 2019.

Eligard 4013-A Med B Jurisdiction H (AR, CO, LA, MS, NM, OK, TX) and L (DC, DE, MD, NJ, PA) P2022.docx © 2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

